Figures & data
Figure 1. Flow chart of participants included in the study. E2, 17β-estradiol; ITT, intention-to-treat; NETA, norethisterone acetate; PP, per protocol.
![Figure 1. Flow chart of participants included in the study. E2, 17β-estradiol; ITT, intention-to-treat; NETA, norethisterone acetate; PP, per protocol.](/cms/asset/8bd4d62b-1a17-49a5-9278-4850975fb1ac/icmt_a_2190507_f0001_b.jpg)
Table 1. Demographic and clinical baseline characteristics of participants according to treatment group.
Figure 2. Number of hot flushes per week before and at the end of treatment (intention-to-treat [ITT] analysis population). 17β-E2, 17β-estradiol; NETA, norethisterone acetate.
![Figure 2. Number of hot flushes per week before and at the end of treatment (intention-to-treat [ITT] analysis population). 17β-E2, 17β-estradiol; NETA, norethisterone acetate.](/cms/asset/59242b19-7c7e-4f21-9dfa-9192ef16956e/icmt_a_2190507_f0002_b.jpg)
Figure 3. Mean number of hot flushes by week in both groups (0.5 mg 17β-estradiol [17β-E2]/0.1 mg norethisterone acetate [NETA] and placebo group). Intention-to-treat (ITT) analysis population.
![Figure 3. Mean number of hot flushes by week in both groups (0.5 mg 17β-estradiol [17β-E2]/0.1 mg norethisterone acetate [NETA] and placebo group). Intention-to-treat (ITT) analysis population.](/cms/asset/5e1c45de-5844-479b-a94b-e501b07f80c9/icmt_a_2190507_f0003_b.jpg)
Figure 4. Percentage change of hot flush weekly weighted score (HFWWS) at weeks 4, 8, 12 and 24 of treatment compared to baseline. Intention-to-treat (ITT) analysis population. HFWWS = (mild hot flushes × 1) + (moderate hot flushes × 2) + (severe hot flushes × 3). 17β-E2, 17β-estradiol; NETA, norethisterone acetate.
![Figure 4. Percentage change of hot flush weekly weighted score (HFWWS) at weeks 4, 8, 12 and 24 of treatment compared to baseline. Intention-to-treat (ITT) analysis population. HFWWS = (mild hot flushes × 1) + (moderate hot flushes × 2) + (severe hot flushes × 3). 17β-E2, 17β-estradiol; NETA, norethisterone acetate.](/cms/asset/5321df5c-7c27-4d2b-9f24-f2b2e0e4fb7d/icmt_a_2190507_f0004_b.jpg)
Table 2. Severity score of vasomotor symptoms before and at end of treatment (intention-to-treat [ITT] analysis population): hot flush weekly weighted score.